Prime Medicine, Inc. Debt Securities, Available-for-sale, Amortized Cost
Prime Medicine, Inc. (PRME) had Debt Securities, Available-for-sale, Amortized Cost of $47.63 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $47.63M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $71.39M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $114.57M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $137.00M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $47.63M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $71.39M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $114.57M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $137.00M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $44.55M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $48.48M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $3.00M 10-Q · filed 2025-11-07 |
| 2024-09-30 | $52.62M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $102.64M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $110.03M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $74.65M 10-Q · filed 2024-11-12 |
| 2023-09-30 | $116.69M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $80.92M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $110.13M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $98.85M 10-Q · filed 2023-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |